Net profit of Indegene declined 6.20% to Rs 102.90 crore in the quarter ended December 2025 as against Rs 109.70 crore during the previous quarter ended December 2024. Sales rose 30.77% to Rs 942.10 crore in the quarter ended December 2025 as against Rs 720.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales942.10720.40 31 OPM %16.9318.30 - PBDT174.30166.30 5 PBT134.70146.30 -8 NP102.90109.70 -6 Powered by Capital Market - Live News

Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene`s Board of Directors.Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck`s first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene. Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners` growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live News

Indegene announced that the company`s wholly owned subsidiaries, Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH have, on 31 December 2025, signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) (Trilogy Canada) (Target Company), wholly owned subsidiary of Trilogy Writing and Consulting GmbH. Consequent to the above Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc.Trilogy Canada specialises in medical writing. Powered by Capital Market - Live News

Net profit of Indegene rose 11.34% to Rs 102.10 crore in the quarter ended September 2025 as against Rs 91.70 crore during the previous quarter ended September 2024. Sales rose 17.09% to Rs 804.20 crore in the quarter ended September 2025 as against Rs 686.80 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales804.20686.80 17 OPM %17.4818.36 - PBDT156.50143.50 9 PBT133.10124.10 7 NP102.1091.70 11 Powered by Capital Market - Live News